Summary

Asia Pacific Clinical Trials Market Summary

The Asia Pacific clinical trials market size was valued at USD 16.82 billion in 2024 and is projected to reach USD 34.23 billion by 2033, growing at a CAGR of 8.46% from 2025 to 2033. The Asia Pacific clinical trials market is driven by a growing number of pharmaceutical and medical device companies, advancements in digital health, personalized medicine, and rising partnerships, which are expected to drive the market over the estimated period.

In addition, supportive government initiatives, advanced regulatory approvals, and increased funding from pharmaceutical and biotech companies further contribute to the global market. Furthermore, collaborations, increased patient awareness, and improved trial accessibility are expected to drive the recruitment efforts, data quality, and success rates of trial populations and global regions. Furthermore, increasing collaboration between industry stakeholders, digital health innovators, and patient advocacy groups. Pharmaceutical companies are expanding their in-house R&D pipelines and actively partnering with CROs to streamline study design, site management, and regulatory submissions.

This trend allows sponsors to accelerate timelines without compromising data integrity or patient safety. Similarly, rising patient awareness and education, often supported by advocacy foundations and public health campaigns, have resulted in greater trial participation, particularly in complex areas such as oncology and rare diseases. The shift toward more inclusive enrollment strategies, supported by federal guidelines and diversity mandates, ensures clinical outcomes better reflect real-world populations.

Asia Pacific Clinical Trials Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Asia Pacific clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and country:

• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV
• Study Design Outlook (Revenue, USD Million, 2021 - 2033)
• Interventional Trials
• Observational Trials
• Expanded Access Trials
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Autoimmune/Inflammation
o Rheumatoid Arthritis
o Multiple Sclerosis
o Osteoarthritis
o Irritable Bowel Syndrome (IBS)
o Others
• Pain Management
o Chronic Pain
o Acute Pain
• Oncology
o Blood Cancer
o Solid Tumors
o Others
• CNS Conditions
o Epilepsy
o Parkinson's Disease (PD)
o Huntington's Disease
o Stroke
o Traumatic Brain Injury (TBI)
o Amyotrophic Lateral Sclerosis (ALS)
o Muscle Regeneration
o Others
• Diabetes
• Obesity
• Cardiovascular Diseases
• Others
• Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
• Autoimmune/Inflammation
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Pain Management
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Oncology
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• CNS Conditions
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Diabetes
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Obesity
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Cardiovascular Diseases
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Others
o Interventional Trials
o Observational Trials
o Expanded Access Trials
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Analytical Testing Services
• Clinical Trial Data Management Services
• Others
• Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• Asia Pacific
o Japan
o China
o India
o Thailand
o South Korea
o Australia

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Fast track of clinical trials
3.3. Virtual/decentralized clinical trials
3.4. Real-world Evidence (RWE)
3.5. verage Cost of Clinical Trial /Price of Clinical Trails
3.5.1. By Phase
3.5.2. By TheArapeutic Area
3.5.3. By Region
3.6. Market Dynamics
3.6.1. Market Driver Analysis
3.6.1.1. Increasing Research and Development Promoting Outsourcing
3.6.1.2. Adoption of New Technology in Clinical Research
3.6.1.3. Increasing Prevalence of Chronic Disease
3.6.1.4. Globalization of Clinical Trials
3.6.1.5. Shift Toward Personalized Medicine
3.6.2. Market Restraint Analysis
3.6.2.1. Stringent Regulations in New Drug Development
3.6.2.2. Lack of Skilled Workforce in Clinical Research
3.6.3. Market Challenge Analysis
3.6.3.1. Rising Cost of Clinical Trial
3.7. Clinical Trials Market Analysis Tools
3.7.1. Industry Analysis - Porter’s
3.7.1.1. Bargaining power of suppliers
3.7.1.2. Bargaining power of buyers
3.7.1.3. Threat of substitutes
3.7.1.4. Threat of new entrants
3.7.1.5. Competitive rivalry
3.7.2. PESTEL Analysis
3.7.2.1. Political & Legal Landscape
3.7.2.2. Economic and Social Landscape
3.7.2.3. Technological landscape
3.7.3. COVID-19 Impact Analysis
3.7.3.1. Disrupted Clinical Trials
3.7.3.2. Obstacles in Clinical Trials
Chapter 4. Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2023 & 2030
4.3. Phase I
4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Phase II
4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Phase III
4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Phase IV
4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2023 & 2030
5.3. Interventional
5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Observational
5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Expanded Access
5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2023 & 2030
6.3. Autoimmune/Inflammation
6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. Rheumatoid Arthritis
6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Multiple Sclerosis
6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. Osteoarthritis
6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Irritable Bowel Syndrome (IBS)
6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Pain Management
6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Chronic Pain
6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Acute Pain
6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Oncology
6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Blood Cancer
6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Solid Tumors
6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Others
6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. CNS Conditions
6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Epilepsy
6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Parkinson's Disease (PD)
6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. Huntington's Disease
6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Stroke
6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Traumatic Brain Injury (TBI)
6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Amyotrophic Lateral Sclerosis (ALS)
6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.8. Muscle Regeneration
6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.9. Others
6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Obesity
6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.9. Cardiovascular
6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.10. Others
6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Clinical Trials Market: Sponsor Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
7.3. Pharmaceutical
7.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Medical Device Companies
7.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Clinical Trials Market: by Service Type Estimates & Trend Analysis
8.1. Definitions & Scope
8.2. Study Design Market Share Analysis, 2024 & 2030
8.3. Segment Dashboard
8.4. Global Clinical Trials Market, By Service Type, 2018 to 2030
8.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
8.5.1. Protocol Designing
8.5.2. Site Identification
8.5.3. Patient Recruitment
8.5.4. Laboratory Services
8.5.5. Bioanalytical Testing Services
8.5.6. Clinical Trial Data Management Services
8.5.7. Others
Chapter 9. Clinical Trials Market: Regional Estimates & Trend Analysis
9.1. Regional Outlook
9.2. Clinical Trials Market: Regional Movement Analysis & Market Share, 2023 & 2030
9.3. North America
9.3.1. North America Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.2. U.S.
9.3.2.1. Key Country Dynamics
9.3.2.2. Competitive Scenario
9.3.2.3. Regulatory Scenario
9.3.2.4. U.S. Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.3. Canada
9.3.3.1. Key Country Dynamics
9.3.3.2. Competitive Scenario
9.3.3.3. Regulatory Scenario
9.3.3.4. Canada Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Europe
9.4.1. Europe Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.2. UK
9.4.2.1. Key Country Dynamics
9.4.2.2. Competitive Scenario
9.4.2.3. Regulatory Scenario
9.4.2.4. UK Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.3. Germany
9.4.3.1. Key Country Dynamics
9.4.3.2. Competitive Scenario
9.4.3.3. Regulatory Scenario
9.4.3.4. Germany Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.4. France
9.4.4.1. Key Country Dynamics
9.4.4.2. Competitive Scenario
9.4.4.3. Regulatory Scenario
9.4.4.4. France Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.5. Italy
9.4.5.1. Key Country Dynamics
9.4.5.2. Competitive Scenario
9.4.5.3. Regulatory Scenario
9.4.5.4. Italy Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.6. Spain
9.4.6.1. Key Country Dynamics
9.4.6.2. Competitive Scenario
9.4.6.3. Regulatory Scenario
9.4.6.4. Spain Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.7. Denmark
9.4.7.1. Key Country Dynamics
9.4.7.2. Competitive Scenario
9.4.7.3. Regulatory Scenario
9.4.7.4. Denmark Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.8. Sweden
9.4.8.1. Key Country Dynamics
9.4.8.2. Competitive Scenario
9.4.8.3. Regulatory Scenario
9.4.8.4. Sweden Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.9. Norway
9.4.9.1. Key Country Dynamics
9.4.9.2. Competitive Scenario
9.4.9.3. Regulatory Scenario
9.4.9.4. Norway Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Asia Pacific
9.5.1. Asia Pacific Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.2. Japan
9.5.2.1. Key Country Dynamics
9.5.2.2. Competitive Scenario
9.5.2.3. Regulatory Scenario
9.5.2.4. Japan Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.3. China
9.5.3.1. Key Country Dynamics
9.5.3.2. Competitive Scenario
9.5.3.3. Regulatory Scenario
9.5.3.4. China Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.4. India
9.5.4.1. Key Country Dynamics
9.5.4.2. Competitive Scenario
9.5.4.3. Regulatory Scenario
9.5.4.4. India Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.5. South Korea
9.5.5.1. Key Country Dynamics
9.5.5.2. Competitive Scenario
9.5.5.3. Regulatory Scenario
9.5.5.4. South Korea Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.6. Australia
9.5.6.1. Key Country Dynamics
9.5.6.2. Competitive Scenario
9.5.6.3. Regulatory Scenario
9.5.6.4. Australia Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.7. Thailand
9.5.7.1. Key Country Dynamics
9.5.7.2. Competitive Scenario
9.5.7.3. Regulatory Scenario
9.5.7.4. Thailand Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Latin America
9.6.1. Latin America Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. Brazil
9.6.2.1. Key Country Dynamics
9.6.2.2. Competitive Scenario
9.6.2.3. Regulatory Scenario
9.6.2.4. Brazil Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.3. Mexico
9.6.3.1. Key Country Dynamics
9.6.3.2. Competitive Scenario
9.6.3.3. Regulatory Scenario
9.6.3.4. Mexico Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.4. Argentina
9.6.4.1. Key Country Dynamics
9.6.4.2. Competitive Scenario
9.6.4.3. Regulatory Scenario
9.6.4.4. Argentina Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. Middle East & Africa
9.7.1. Middle East & Africa Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.2. South Africa
9.7.2.1. Key Country Dynamics
9.7.2.2. Competitive Scenario
9.7.2.3. Regulatory Scenario
9.7.2.4. South Africa Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.3. Saudi Arabia
9.7.3.1. Key Country Dynamics
9.7.3.2. Competitive Scenario
9.7.3.3. Regulatory Scenario
9.7.3.4. Saudi Arabia Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.4. UAE
9.7.4.1. Key Country Dynamics
9.7.4.2. Competitive Scenario
9.7.4.3. Regulatory Scenario
9.7.4.4. UAE Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7.5. Kuwait
9.7.5.1. Key Country Dynamics
9.7.5.2. Competitive Scenario
9.7.5.3. Regulatory Scenario
9.7.5.4. Kuwait Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Market Participant Categorization
10.2. Key Company Profiles
10.2.1. IQVIA
10.2.1.1. Company Overview
10.2.1.2. Financial Performance
10.2.1.3. Service Benchmarking
10.2.1.4. Strategic Initiatives
10.2.2. Chiltern International Ltd (Laboratory Corporation of America)
10.2.2.1. Company Overview
10.2.2.2. Financial Performance
10.2.2.3. Service Benchmarking
10.2.2.4. Strategic Initiatives
10.2.3. PAREXEL International Corporation
10.2.3.1. Company Overview
10.2.3.2. Financial Performance
10.2.3.3. Service Benchmarking
10.2.3.4. Strategic Initiatives
10.2.4. Pharmaceutical Product Development, LLC (Thermo Fisher Scientific Inc.)
10.2.4.1. Company Overview
10.2.4.2. Financial Performance
10.2.4.3. Service Benchmarking
10.2.4.4. Strategic Initiatives
10.2.5. Charles River Laboratories International Inc.
10.2.5.1. Company Overview
10.2.5.2. Financial Performance
10.2.5.3. Service Benchmarking
10.2.5.4. Strategic Initiatives
10.2.6. ICON Plc
10.2.6.1. Company Overview
10.2.6.2. Financial Performance
10.2.6.3. Service Benchmarking
10.2.6.4. Strategic Initiatives
10.2.7. Wuxi AppTec Inc.
10.2.7.1. Company Overview
10.2.7.2. Financial Performance
10.2.7.3. Service Benchmarking
10.2.7.4. Strategic Initiatives
10.2.7.5. SGS SA
10.2.7.6. Company Overview
10.2.7.7. Financial Performance
10.2.7.8. Service Benchmarking
10.2.7.9. Strategic Initiatives
10.2.8. Syneos Health
10.2.8.1. Company Overview
10.2.8.2. Financial Performance
10.2.8.3. Service Benchmarking
10.2.8.4. Strategic Initiatives
10.2.9. Eli Lilly and Company
10.2.9.1. Company Overview
10.2.9.2. Financial Performance
10.2.9.3. Service Benchmarking
10.2.9.4. Strategic Initiatives
10.2.10. Novo Nordisk A/S
10.2.10.1. Company Overview
10.2.10.2. Financial Performance
10.2.10.3. Service Benchmarking
10.2.10.4. Strategic Initiatives
10.2.11. Clinipace (Caidya)
10.2.11.1. Company Overview
10.2.11.2. Financial Performance
10.2.11.3. Service Benchmarking
10.2.11.4. Strategic Initiatives
10.2.12. AstraZeneca
10.2.12.1. Company Overview
10.2.12.2. Financial Performance
10.2.12.3. Service Benchmarking
10.2.12.4. Strategic Initiatives
10.2.13. Pfizer Inc.
10.2.13.1. Company Overview
10.2.13.2. Financial Performance
10.2.13.3. Service Benchmarking
10.2.13.4. Strategic Initiatives
10.3. Heat Map Analysis/ Company Market Position Analysis
10.4. Estimated Company Market Share Analysis, 2022
10.5. List of Other Key Market Players